Dose Escalating, Phase 1 study evaluating efficacy and safety of Selinexor (Kpt-330) in Patients (Pts) with Relapsed / Refractory Acute Myeloid Leukemia

Trial Profile

Dose Escalating, Phase 1 study evaluating efficacy and safety of Selinexor (Kpt-330) in Patients (Pts) with Relapsed / Refractory Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2015

At a glance

  • Drugs Selinexor (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 01 Dec 2015 New trial record
    • 15 Jun 2014 Interim results presented at the 19th Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top